Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis

BACKGROUND: Inclisiran is a novel, cholesterol-lowering therapy, with a long duration of effect, administered every 6 months (subcutaneously by a healthcare professional). In the ORION-10 trial in US patients with atherosclerotic cardiovascular disease (ASCVD) in addition to maximum tolerated statin...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Nihar R., Campbell, Caresse, Electricwala, Batul, Petrou, Margaret, Trueman, David, Woodcock, Fionn, Cristino, Joaquim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468070/
https://www.ncbi.nlm.nih.gov/pubmed/35595929
http://dx.doi.org/10.1007/s40256-022-00534-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468070/
https://www.ncbi.nlm.nih.gov/pubmed/35595929
http://dx.doi.org/10.1007/s40256-022-00534-9

Ejemplares similares